



News Release

**Takeda's Participation in The Global Health Innovative Technology Fund
~ Japan's first public-private partnership to advance the development of new health technologies for
the developing world ~**

Osaka, Japan, April 8, 2013 --- Takeda Pharmaceutical Company Limited ("Takeda") today announced its participation in the General Incorporated Association, The Global Health Innovative Technology Fund ("GHIT Fund"), the first public-private partnership of its kind in Japan, with an aim to make a long-term concrete contribution to strengthening the foundation of healthcare in developing countries.

The GHIT Fund is a partnership between the Government of Japan, a consortium of Japanese pharmaceutical companies (in alphabetical order: Astellas Pharma Inc.; Daiichi Sankyo Company Ltd.; Eisai Co., Ltd.; Shionogi & Co., Ltd.; Takeda), the Bill & Melinda Gates Foundation, to advance the research and development of new medicines, vaccines and diagnostics to fight infectious diseases in the developing world. The GHIT Fund aims to reinforce Japan's contribution to global health by developing new health technologies, utilizing the highly developed science and technology capacity found at the country's pharmaceutical companies, universities and research institutions. In providing grants for promising research, the GHIT Fund will help bridge the gap between basic research and clinical studies, allowing for unprecedented medicines, vaccines and diagnostics.

The core rationale for the corporate social responsibility program at Takeda is in the corporate mission of "striving towards better health for patients worldwide through leading innovation in medicine." Takeda, as a corporate citizen, aims to solve the social challenges in healthcare where the company can leverage its own expertise. Based on this philosophy, Takeda is partnering with the Global Fund to Fight AIDs, Tuberculosis and Malaria (Global Fund) and Plan Japan to support their efforts to improve access to healthcare for people in developing countries. Takeda's participation in the GHIT Fund is a part of these efforts.

As a company committed to improving people's lives as well as a company with global presence, Takeda continues to contribute to better life and health for people worldwide.

<Overview of GHIT Fund>

Name: Global Health Innovative Technology Fund (GHIT Fund)
Founded: November 2012
Address: Ark Hills Sengokuyama Mori Tower, 25th Floor,
1-9-10 Roppongi, Minato-ku, Tokyo 106-0032, Japan
Activities: 1. Facilitation of R&D global partnerships between Japanese and non-Japanese private and public research organizations.
2. Provision of grants to the aforementioned R&D global partnerships.
3. Advancement and strengthening of Japan's contribution to global health.

For further details about GHIT Fund, please visit <http://www.ghitfund.org/>.

###